Get the Stockscreener App
0.7663
2.11%
-0.0165
Ibio Inc stock is traded at $0.7663, with a volume of 309.25K.
It is down -2.11% in the last 24 hours and down -35.06% over the past month.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
See More
Previous Close:
$0.7828
Open:
$0.784
24h Volume:
309.25K
Relative Volume:
0.27
Market Cap:
$49.28M
Revenue:
$300.00K
Net Income/Loss:
$-27.61M
P/E Ratio:
-1.3265
EPS:
-0.5777
Net Cash Flow:
$-22.17M
1W Performance:
-12.02%
1M Performance:
-35.06%
6M Performance:
-63.68%
1Y Performance:
-9.37%
1-Day Range:
$0.7601
$0.7999
1-Week Range:
$0.7328
$0.95
52-Week Range:
$0.7328
$3.82
Ibio Inc Stock (IBIO) Company Profile
Name
Ibio Inc
Sector
Industry
Phone
302 355-0650
Address
600 MADISON AVENUE, SUITE 1601, NEW YORK
Compare IBIO vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBIO
Ibio Inc
|
0.7663 | 49.28M | 300.00K | -27.61M | -22.17M | -0.5777 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ibio Inc Stock (IBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-26 | Initiated | H.C. Wainwright | Buy |
| Jun-08-26 | Initiated | Raymond James | Outperform |
| Jun-05-26 | Initiated | B. Riley Securities | Buy |
| Oct-21-25 | Initiated | Oppenheimer | Outperform |
| Oct-17-25 | Initiated | Leerink Partners | Outperform |
| May-28-24 | Initiated | Chardan Capital Markets | Buy |
| Nov-29-21 | Initiated | JMP Securities | Mkt Outperform |
| Jan-22-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-20 | Initiated | Alliance Global Partners | Buy |
View All
Ibio Inc Stock (IBIO) Latest News
Form 4 Ibio Inc: Gary Sender (Director) For: 14 October By Investing.com - Investing.com Canada
Form 4 Ibio Inc: Gary Sender (Director) For: 14 October By Investing.com - Investing.com South Africa
Form 4 Ibio Inc: Antonio Bernardino Guimaraes Parada (Director) For: 14 October By Investing.com - Investing.com South Africa
At $0.78 per share, 38,000 options go to iBio (IBIO) director Elizabeth Stoner. - Stock Titan
38,000 options granted to iBio (IBIO) director Alexandra Kropotova vest monthly over 12 months. - Stock Titan
A director receives 38,000 iBio (IBIO) stock options with a $0.78 exercise price. - Stock Titan
A 6.25M-share passive stake in iBio (IBIO) has one direct holder and five reporting parties. - Stock Titan
Johnson & Johnson Stock Has Surged 44%, Can Its Growth Justify the Valuation? - Insider Monkey
iBio, Inc. Common Stock (NASDAQ: IBIO) Share Price, IBIO Stock News, IBIO Share Price & Updates - Kalkine
New iBio (NASDAQ: IBIO) investor presentation goes public - Stock Titan
iBio (NASDAQ:IBIO) Stock Rating Lowered by Wall Street Zen - marketbeat.com
iBio, Inc. (IBIO) Stock Price & News - Syfe
iBio at Wells Fargo healthcare conference: obesity pipeline takes shape By Investing.com - Investing.com South Africa
iBio at Wells Fargo healthcare conference: obesity pipeline takes shape By Investing.com - Investing.com Canada
iBio at Wells Fargo healthcare conference: obesity pipeline takes shape - Investing.com
iBio at Wells Fargo healthcare conference: obesity pipeline takes shape By Investing.com - Investing.com India
iBio at Wells Fargo healthcare conference: obesity pipeline takes shape By Investing.com - Investing.com UK
iBio (NASDAQ: IBIO) Shareholders Set to Vote on 500 Million Share Increase on October 14, 2026 - Kalkine Media
iBio (NASDAQ:IBIO) Upgraded by Wall Street Zen to Hold Rating - marketbeat.com
iBio, Inc. SEC Filing (Sep 4, 2026) - stocktitan.net
Hundreds of millions of new shares on ballot at iBio (IBIO) - Stock Titan
iBio, Inc. Common Stock (NASDAQ: IBIO) Share Price, IBIO Stock News, IBIO Share Price & Updates - kalkine.ca
iBio, Inc. (NASDAQ:IBIO) Receives Average Rating of "Buy" from Brokerages - marketbeat.com
iBio Q2 EPS Forecast Decreased by Brookline Capital Markets - MarketBeat
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference - Yahoo Finance
Insiders Give Up US$33k As iBio Stock Drops To US$1.27 - simplywall.st
iBio Inc. (IBIO) Slides 6.6% to $1.27 as Biotech Stock Approaches Key SupportWyckoff Distribution - dars.gov.et
B. Riley Securities Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $6 - moomoo.com
iBio Advances IBIO-600 Through First Phase 1 Dose Escalation As Cash And Investments Reach $88 Million - Pulse 2.0
iBio Inc. (IBIO) Slides 6.6% to $1.27 as Biotech Stock Approaches Key SupportVolume Rate Change - dars.gov.et
iBio, Inc. Revenue Breakdown – NASDAQ:IBIO - TradingView
iBio FY2026 Net Loss Widens to $33M on Higher R&D Spending - Minichart
iBio FY 2026: Revenue $100K, Net income ($33.04M), EPS ($0.32) — 10-K Summary - tradingview.com
iBio reports $33 million loss for fiscal 2026, advances pipeline By Investing.com - Investing.com Canada
IBio Reports $33.0 Million Fiscal 2026 Net Loss as Phase 1 Advances - Moomoo
iBio Reports $33.0 Million Fiscal 2026 Net Loss as Phase 1 Advances - Quiver Quantitative
IBIO: Advanced clinical pipeline and secured funding, extending cash runway into fiscal 2028 - TradingView
iBio (NASDAQ:IBIO) Releases Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
iBio reports FY2026 net loss of $33.0M, revenue $0.1M and $88.0M cash and investments - TradingView
iBio reports $33 million loss for fiscal 2026, advances pipeline By Investing.com - Investing.com Nigeria
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - manilatimes.net
iBio Reports Fiscal 2026 Financial Results and Corporate Update Highlighting Clinical and Pipeline Progress - Quiver Quantitative
IBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - marketscreener.com
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - au.finance.yahoo.com
iBio FY26 Results: Net loss widens 80% to $33.0M, R&D up 136% - scanx.trade
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - GlobeNewswire
iBio (IBIO) Expected to Release Quarterly Earnings on Friday - MarketBeat
iBio (NASDAQ:IBIO) Cut to "Sell" at Wall Street Zen - MarketBeat
iBio (NYSE: IBIO) seeks 500M shares, revises equity plan for warrants - Stock Titan
iBio (IBIO) Chart: Closes 1.72% Lower at $1.43 for the Current Session; Current Setup: the Near-Term Reference Band Stretches From $1.36 to $1.50 in the Available RecordMax Pain Level - vinanet.vn
Ibio Inc Stock (IBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ibio Inc Stock (IBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Duran Felipe | Chief Financial Officer |
Mar 19 '26 |
Buy |
2.02 |
24,835 |
50,132 |
35,974 |
| Brenner Martin | See Remarks |
Mar 19 '26 |
Buy |
2.02 |
12,336 |
24,919 |
30,652 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):